Page 87 - Read Online

Page 263 Nickoloff et al. Cancer Drug Resist 2021;4:244-63 I http://dx.doi.org/10.20517/cdr.2020.89

Oncol 2017;29:626-34.
227. Weitzman MD, Fradet-Turcotte A. Virus DNA replication and the host DNA damage response. Annu Rev Virol 2018;5:141-64.
228. Jafari A, Rezaei-Tavirani M, Farhadihosseinabadi B, Taranejoo S, Zali H. HSP90 and co-chaperones: impact on tumor progression and
prospects for molecular-targeted cancer therapy. Cancer Invest 2020;38:310-28.
229. Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol
2013;14:e358-69.
230. Jhaveri K, Modi S. HSP90 inhibitors for cancer therapy and overcoming drug resistance. Adv Pharmacol 2012;65:471-517.
231. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature
2003;425:407-10.
232. Moulick K, Ahn JH, Zong H, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol
2011;7:818-26.
233. Sessa C, Shapiro GI, Bhalla KN, et al. First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with
advanced solid tumors. Clin Cancer Res 2013;19:3671-80.
234. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30:3277-86.
235. Balmus G, Pilger D, Coates J, et al. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken
replication forks. Nat Commun 2019;10:87.
236. Nickoloff JA. Improving cancer therapy by combining cell biological, physical, and molecular targeting strategies. Chin J Cancer Res
2013;25:7-9.
237. Kon T, Zhang X, Huang Q, et al. Oncolytic virus-mediated tumor radiosensitization in mice through DNA-PKcs-specific shRNA. Transl
Cancer Res 2012;1:4-14.
238. Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents
for triple negative breast cancer. Theranostics 2016;6:1-13.
239. Guo P, Yang J, Huang J, Auguste DT, Moses MA. Therapeutic genome editing of triple-negative breast tumors using a noncationic and
deformable nanolipogel. Proc Natl Acad Sci USA 2019;116:18295-303.